Results 101 to 110 of about 136,887 (323)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Prevalence of myocarditis in critically-ill pediatric patients in Qena University Hospital

SVU - International Journal of Medical Sciences
Background: Myocarditis is a potentially life-threatening inflammatory disease affecting the myocardium. There are many different etiologies, most of which are infectious. The spectrum of presentations can range between subclinical disease and congestive
Ahmed El-Abd Ahmed , Abdallah Elaiw Mohamed Ali , Heba Mohamed Qubasy , Mohamed Said Sami Saleh Younes *   +3 more
doaj   +1 more source

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

ESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta, Ellen Brinza, Prateeti Khazanie, Pamela N. Peterson, P Michael Ho, David P. Kao   +5 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
T raditional cytotoxic chemotherapy and novel cancer therapies have various cardiotoxicities, ranging from heart failure to arrhythmias. One of the most exciting developments in cancer treatment is immunotherapy, which uses the immune system to attack ...
Nicolas L. Palaskas, J. Lopez-Mattei, J. Durand, C. Iliescu, A. Deswal   +4 more
semanticscholar   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Immune checkpoint inhibitor-related myocarditis in patients with lung cancer

BMC Cancer
Background The clinical characteristics of immune checkpoint inhibitors (ICIs)-related myocarditis in lung cancer remains uncertain. The purpose of this study was to evaluate the incidence, clinical characteristics, risk factors, and prognosis of ...
Wenli Cao, Sen Han, Panpan Zhang, Lan Mi, Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Di Wu, Jieran Long, Ziran Zhang, Qianyun Hao, Jian Fang, Kai Wang   +18 more
doaj   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

100 Global longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF [PDF]

, 2021
Aldostefano Porcari, Marco Merlo, Chiara Baggio, Giulia Gagno, Marco Cittar, Giulia Barbati, Alessia Paldino, Matteo Castrichini, Giancarlo Vitrella, Lorenzo Pagnan, Antonio Cannatà, Alessandro Andreis, Annagrazia Cecere, Alberto Cipriani, Anne G. Raafs, Daniel I. Bromage, Stefania Rosmini, Paul A. Scott, Daniel Sado, Gianluca Di Bella, Gaetano Nucifora, Martina Perazzolo Marra, Stéphane Heymans, Massimo Imazio, Gianfranco Sinagra   +24 more
openalex   +1 more source

COVID-19 myocarditis

Global Cardiology
Background: Myocarditis can be observed in patients with COVID-19. Myocarditis can also be seen in patients vaccinated against SARS-CoV-2 infection, the etiological agent of this disease.
Reinaldo B. Bestetti, Rosemary Furlan-Daniel, Luciano P. Pereira   +2 more
doaj   +1 more source